NCT06218940View on ClinicalTrials.gov

HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2027

Conditions

NSCLC Stage IV

Interventions

DRUG

HY1272

Each patient will receive HY1272 weely or HY1272 weely+Oshitinib 80mg P.O. daily

All Listed Sponsors

lead

Newsoara Biopharma Co., Ltd.

INDUSTRY